A review of antibiotic synergy in carbapenemase-producing bacteria

The problem of antibiotic resistance has garnered too much attention over the last few decades for posing a global hazard to the clinical handling and the inhibition of several deadly infections caused by bacteria. It burdens the world not only clinically but also economically... Antibiotic agents known as carbapenems are a very effective and  typically designated for the treatment of multidrug-resistant (MDR) bacterial infections. To identify a suitable antibiotic combination to be used in vivo, one must be able to determine the synergism between the antibiotics in vitro. Several methods, such as the checkerboard method, multiple-combination bactericidal test, time-kill and E-test, have been used for this purpose. However, the lack of proper standardization procedures, types of bacterial agents, bacterial load, stage of infection and other factors make it very difficult to reproduce or correlate the results with other methods.Carbapenem-destroying lactases, which have recently emerged as mechanisms of resistance, are increasing in number and decreasing the treatment alternatives available. These infections are treated with colistin and tigecycline, but monotherapy may result in clinical breakdown because of a variety of factors. To control these infections, clinicians often choose combinations of drugs over monotherapy. There is an extreme lack of information on synergistic antibiotic combinations accounting for the diverse mechanisms of GNB resistance commonly encountered. The incidence of carbapenem-resistant GNB in Indian articles is also unknown. Therefore, we anticipate that this study may provide methodology for the selection of an appropriate antibiotic combination

Competitive Exclusion of Parthenium hysterophorus by Other Invasive Species - A Case Study from Andhra Pradesh, India

The abundance, dominance and growth performance of Parthenium hysterophorus in relation to its field associates in extensively large areas was investigated. The preliminary analysis of the data revealed that P. hysterophorus is a weak or poor competitor and hence it fails to grow in the company of any aggressive species. Senna uniflora and a few other plants were identified for the control of this pernicious weed. The ability of other species to control P. hysterophorus was attributed to allelopathy. In order to understand how Hyptis suaveolens and Senna uniflora are capable of arresting the growth of P. hysterophorus, pot culture experiments in de Wit replacement series, field experiments in experimental plots and experimental manipulation of the competitive species under natural conditions during different seasons were carried out for two years in 2004 and 2005. The results clearly revealed that both H. suaveolens and S. uniflora were highly effective in the management of P. hysterophorus. The results further showed that the physical dominance and the ability of the competitive species to deprive P. hysterophorus of light are mainly responsible for the decline of P. hysterophorus. Allelopathy doesn't seem to play any effective role under natural conditions

Pd-mediated functionalization of polysubstituted pyrroles: their evaluation as potential inhibitors of PDE4

Novel polysubstituted pyrroles have been designed and accessed via a one-pot multicomponent reaction followed by Pd-mediated C-C bond forming reactions. All the compounds synthesized were tested for their PDE4B inhibitory properties in vitro and two of them obtained via Heck reaction showed significant inhibition. The docking results suggested that these alkenyl derivatives containing ester moiety interact well with the PDE4B protein in silico where the ester carbonyl oxygen played a key role. The pyrrole framework presented here could be a new template for the identification of small molecule based novel inhibitors of PDE4. The single crystal X-ray data of a representative compound is presented

LiDAR-based reference aboveground biomass maps for tropical forests of South Asia and Central Africa

International audienceAccurate mapping and monitoring of tropical forests aboveground biomass (AGB) is crucial to design effective carbon emission reduction strategies and improving our understanding of Earth’s carbon cycle. However, existing large-scale maps of tropical forest AGB generated through combinations of Earth Observation (EO) and forest inventory data show markedly divergent estimates, even after accounting for reported uncertainties. To address this, a network of high-quality reference data is needed to calibrate and validate mapping algorithms. This study aims to generate reference AGB datasets using field inventory plots and airborne LiDAR data for eight sites in Central Africa and five sites in South Asia, two regions largely underrepresented in global reference AGB datasets. The study provides access to these reference AGB maps, including uncertainty maps, at 100 m and 40 m spatial resolutions covering a total LiDAR footprint of 1,11,650 ha [ranging from 150 to 40,000 ha at site level]. These maps serve as calibration/validation datasets to improve the accuracy and reliability of AGB mapping for current and upcoming EO missions (viz., GEDI, BIOMASS, and NISAR)

Abstracts of National Conference on Research and Developments in Material Processing, Modelling and Characterization 2020

This book presents the abstracts of the papers presented to the Online National Conference on Research and Developments in Material Processing, Modelling and Characterization 2020 (RDMPMC-2020) held on 26th and 27th August 2020 organized by the Department of Metallurgical and Materials Science in Association with the Department of Production and Industrial Engineering, National Institute of Technology Jamshedpur, Jharkhand, India. Conference Title: National Conference on Research and Developments in Material Processing, Modelling and Characterization 2020Conference Acronym: RDMPMC-2020Conference Date: 26–27 August 2020Conference Location: Online (Virtual Mode)Conference Organizer: Department of Metallurgical and Materials Engineering, National Institute of Technology JamshedpurCo-organizer: Department of Production and Industrial Engineering, National Institute of Technology Jamshedpur, Jharkhand, IndiaConference Sponsor: TEQIP-

Ezetimibe added to statin therapy after acute coronary syndromes

BACKGROUND: Statin therapy reduces low-density lipoprotein (LDL) cholesterol levels and the risk of cardiovascular events, but whether the addition of ezetimibe, a nonstatin drug that reduces intestinal cholesterol absorption, can reduce the rate of cardiovascular events further is not known. METHODS: We conducted a double-blind, randomized trial involving 18,144 patients who had been hospitalized for an acute coronary syndrome within the preceding 10 days and had LDL cholesterol levels of 50 to 100 mg per deciliter (1.3 to 2.6 mmol per liter) if they were receiving lipid-lowering therapy or 50 to 125 mg per deciliter (1.3 to 3.2 mmol per liter) if they were not receiving lipid-lowering therapy. The combination of simvastatin (40 mg) and ezetimibe (10 mg) (simvastatin-ezetimibe) was compared with simvastatin (40 mg) and placebo (simvastatin monotherapy). The primary end point was a composite of cardiovascular death, nonfatal myocardial infarction, unstable angina requiring rehospitalization, coronary revascularization ( 6530 days after randomization), or nonfatal stroke. The median follow-up was 6 years. RESULTS: The median time-weighted average LDL cholesterol level during the study was 53.7 mg per deciliter (1.4 mmol per liter) in the simvastatin-ezetimibe group, as compared with 69.5 mg per deciliter (1.8 mmol per liter) in the simvastatin-monotherapy group (P<0.001). The Kaplan-Meier event rate for the primary end point at 7 years was 32.7% in the simvastatin-ezetimibe group, as compared with 34.7% in the simvastatin-monotherapy group (absolute risk difference, 2.0 percentage points; hazard ratio, 0.936; 95% confidence interval, 0.89 to 0.99; P = 0.016). Rates of pre-specified muscle, gallbladder, and hepatic adverse effects and cancer were similar in the two groups. CONCLUSIONS: When added to statin therapy, ezetimibe resulted in incremental lowering of LDL cholesterol levels and improved cardiovascular outcomes. Moreover, lowering LDL cholesterol to levels below previous targets provided additional benefit